Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | ECOG-E1910 study: clinical benefit of early blinatumomab incorporation in ALL

Bijal Shah • 8 Sep 2023
SOHO 2023
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab
ECOG-E1910

Bijal Shah, MD, Moffitt Cancer Center, Tampa, FL, shares findings from the Phase III ECOG-E1910 trial (NCT02003222) and comments on the clinical benefit of early blinatumomab incorporation in patients with acute lymphoblastic leukemia (ALL) who are measurable residual disease (MRD) negative following initial chemotherapy. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Bijal Shah

1:33
The impact of prior therapies on the outcomes of patients with R/R ALL treated with CAR-T therapy
Bijal Shah • 8 Sep 2023
1:27
TP53-aberrant MCL: challenges and treatment approaches
Bijal Shah • 8 Sep 2023
1:03
An insight into the sequencing of immunotherapies in adults with ALL
Bijal Shah • 8 Sep 2023
Updates in ALL
Bijal Shah et al. • 14 Apr 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals